ENDRA Life Sciences (NASDAQ:NDRA) Shares Up 3.3% – Still a Buy?

ENDRA Life Sciences Inc. (NASDAQ:NDRA)’s share price shot up 3.3% during trading on Tuesday . The stock traded as high as $5.13 and last traded at $4.95. Approximately 10,183 shares traded hands during trading, a decline of 79% from the average daily volume of 47,782 shares. The stock had previously closed at $4.79.

Wall Street Analyst Weigh In

NDRA has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Monday, April 20th. Ascendiant Capital Markets lowered their price objective on shares of ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $25.00.

ENDRA Life Sciences Price Performance

The firm has a market cap of $6.97 million, a price-to-earnings ratio of -0.67 and a beta of -0.06. The company has a fifty day moving average price of $5.03 and a two-hundred day moving average price of $4.57.

ENDRA Life Sciences (NASDAQ:NDRA) last released its earnings results on Friday, May 15th. The company reported ($1.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.14. On average, research analysts expect that ENDRA Life Sciences Inc. will post -4.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ENDRA Life Sciences

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Altium Capital Management LLC bought a new stake in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences comprises 0.9% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th largest position. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences at the end of the most recent quarter. Institutional investors own 1.19% of the company’s stock.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.